Mirxes Holding Co Ltd
02629
Company Profile
Business description
Mirxes Holding Co Ltd is a miRNA technology company that is making diagnostic solutions for the screening of diseases accessible across its key markets in Asia, including Singapore and China. It has one Core Product (namely, GASTROClearTM), two other commercialized products (namely, LUNGClearTM and FortitudeTM), and six product candidates at the pre-clinical stage, as illustrated in the chart below. GASTROClearTM, its Core Product, is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. The company generates the majority of its revenue from Singapore.
Contact
2 Tukang Innovation Grove
No. 09-02 JTC MedTech Hub
Singapore618305
SGPT: +65 68162931
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
352
Stocks News & Analysis
stocks
After earnings, is Alphabet stock a buy, a sell, or fairly valued?
With a diverse portfolio of innovative technology and integrated media platforms, here’s what we think of Alphabet’s stock.
stocks
Moated ASX share crashes amid weak trading update
Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks
A collection of our best stock opportunities
Our latest articles about where we see opportunities in the market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,015.40 | 48.70 | 0.54% |
| CAC 40 | 7,861.96 | 4.60 | 0.06% |
| DAX 40 | 24,262.22 | 44.85 | 0.19% |
| Dow JONES (US) | 44,461.28 | 171.71 | -0.38% |
| FTSE 100 | 9,136.94 | 0.62 | 0.01% |
| HKSE | 25,176.93 | 347.52 | -1.36% |
| NASDAQ | 21,129.67 | 31.38 | 0.15% |
| Nikkei 225 | 40,654.70 | 19.85 | -0.05% |
| NZX 50 Index | 12,855.97 | 80.44 | -0.62% |
| S&P 500 | 6,362.90 | 7.96 | -0.12% |
| S&P/ASX 200 | 8,756.40 | 51.80 | 0.60% |
| SSE Composite Index | 3,615.72 | 6.01 | 0.17% |